Dancey Janet E
Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College Street, Suite 800, Toronto, ON M5G 0A3 Canada.
Expert Rev Anticancer Ther. 2009 Jul;9(7):891-4. doi: 10.1586/era.09.66.
In recent years no cancer therapeutic class has undergone more prolific or successful drug development efforts than the kinase inhibitors. The robust research interest is evident in the number of kinase inhibitor presentations at the American Association for Cancer Research Annual Meeting held in Denver (CO, USA) 18-22 April 2009. Presentation highlights from the Kinase Inhibitor 4 Minisymposium include the identification of FGF receptor genetic alterations that correlate with sensitivity to the kinase inhibitor TKI258; evaluation of activity of mitotic kinase inhibitors GSK461364A and AZD1152 in breast and small-cell lung cancer and the identification of new inhibitors to PI3K/AKT/mTOR pathway.
近年来，没有哪一类癌症治疗药物比激酶抑制剂经历过更多产或更成功的药物研发努力。2009年4月18日至22日在美国科罗拉多州丹佛市举行的美国癌症研究协会年会上，激酶抑制剂的展示数量明显体现了浓厚的研究兴趣。激酶抑制剂4小型研讨会的展示亮点包括：鉴定出与激酶抑制剂TKI258敏感性相关的成纤维细胞生长因子受体基因改变；评估有丝分裂激酶抑制剂GSK461364A和AZD1152在乳腺癌和小细胞肺癌中的活性，以及鉴定出PI3K/AKT/mTOR通路的新抑制剂。
